预测子宫内膜失败风险:一种独立于子宫内膜时机的生物标志物特征
多中心前瞻性研究纳入281名激素替代周期白人女性,基于404个基因表达去除子宫内膜黄体期时机影响,将患者分为预后差(n=137)与预后好(n=49)两组,两组妊娠率44.6% vs 79.6%、活产率25.6% vs 77.6%,预后差组子宫内膜失败相对风险为预后好组的3.3倍。
要点
- 子宫内膜失败风险(EFR)特征在73.7%患者中检出,独立于黄体期时机。
- 预后差组妊娠率44.6%、活产率25.6%,均低于预后好组的79.6%和77.6%。
- 预后差组临床流产22.2%、生化流产20.4%,预后好组分别为2.6%和0%。
核心结论
- EFR特征揭示了一种独立于子宫内膜黄体期时机的新型子宫内膜紊乱,存在于73.7%的患者中。
- EFR特征将患者分为两个显著不同且临床相关的预后组,为个体化治疗提供机会。
- 在将该基因特征作为基于人工智能(AI)的工具用于降低子宫内膜失败风险之前,仍需进一步验证。
研究设计与样本
- 多中心前瞻性研究,纳入2018年7月至2021年7月接受激素替代治疗的281名白人女性(年龄39.4±4.8岁,体重指数22.9±3.5 kg/m2)。
- 217名患者的子宫内膜样本符合RNA质量标准,用于特征发现和分析。
- 干预为在分泌中期采集子宫内膜活检。
- 主要结局指标为404个基因经子宫内膜黄体期时机校正后的表达,以及活检后首次单胚胎移植(SET)的生殖结局。
主要发现
- 去除子宫内膜时机变异后,基于临床和转录组特征将患者分为预后差组(n=137)和预后好组(n=49)。
- 预后差组 vs 预后好组:妊娠率44.6% vs 79.6%,活产率25.6% vs 77.6%,临床流产率22.2% vs 2.6%,生化流产率20.4% vs 0%。
- 预测为预后差的患者子宫内膜失败相对风险是预后好患者的3.3倍。
- 预后差特征涉及59个上调基因和63个下调基因,主要参与调控(17.0%)、代谢(8.4%)、免疫反应和炎症(7.8%)。
- EFR特征的中位准确度为0.92(最小0.88,最大0.94),中位灵敏度为0.96(最小0.91,最大0.98),中位特异度为0.84(最小0.77,最大0.88)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 在将该基因特征作为基于人工智能(AI)的工具实施之前,仍需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To propose a new gene expression signature that identifies endometrial disruptions independent of endometrial luteal phase timing and predicts if patients are at risk of endometrial failure. DESIGN: Multicentric, prospective study. SETTING: Reproductive medicine research department in a public hospital affiliated with private fertility clinics and a reproductive genetics laboratory. PATIENTS: Caucasian women (n = 281; 39.4 ± 4.8 years old with a body mass index of 22.9 ± 3.5 kg/m2) undergoing hormone replacement therapy between July 2018 and July 2021. Endometrial samples from 217 patients met RNA quality criteria for signature discovery and analysis. INTERVENTION(S): Endometrial biopsies collected in the mid-secretory phase. MAIN OUTCOME MEASURE(S): Endometrial luteal phase timing-corrected expression of 404 genes and reproductive outcomes of the first single embryo transfer (SET) after biopsy collection to identify prognostic biomarkers of endometrial failure. RESULTS: Removal of endometrial timing variation from gene expression data allowed patients to be stratified into poor (n = 137) or good (n = 49) endometrial prognosis groups on the basis of their clinical and transcriptomic profiles. Significant differences were found between endometrial prognosis groups in terms of reproductive rates: pregnancy (44.6% vs. 79.6%), live birth (25.6% vs. 77.6%), clinical miscarriage (22.2% vs. 2.6%), and biochemical miscarriage (20.4% vs. 0%). The relative risk of endometrial failure for patients predicted as a poor endometrial prognosis was 3.3 times higher than those with a good prognosis. The differences in gene expression between both profiles were proposed as a biomarker, coined the endometrial failure risk (EFR) signature. Poor prognosis profiles were characterized by 59 upregulated and 63 downregulated genes mainly involved in regulation (17.0%), metabolism (8.4%), immune response, and inflammation (7.8%). This EFR signature had a median accuracy of 0.92 (min = 0.88, max = 0.94), median sensitivity of 0.96 (min = 0.91, max = 0.98), and median specificity of 0.84 (min = 0.77, max = 0.88), positioning itself as a promising biomarker for endometrial evaluation. CONCLUSION(S): The EFR signature revealed a novel endometrial disruption, independent of endometrial luteal phase timing, present in 73.7% of patients. This EFR signature stratified patients into 2 significantly distinct and clinically relevant prognosis profiles providing opportunities for personalized therapy. Nevertheless, further validations are needed before implementing this gene signature as an artificial intelligence (AI)-based tool to reduce the risk of patients experiencing endometrial failure.
引用
- Diaz-Gimeno P, Sebastian-Leon P, Spath K, et al. Predicting risk of endometrial failure: a biomarker signature that identifies a novel disruption independent of endometrial timing in patients undergoing hormonal replacement cycles. Fertil Steril. 2024. PMID: 38518993. doi:10.1016/j.fertnstert.2024.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。